EU Regulators Prioritize Nitrosamine Evaluations Deadline
Industry's Request For A Standardized Approach Has Been Set Aside
EU regulators say that sponsors must complete their nitrosamine-related risk evaluations for all EU medicines containing chemically-synthesised active substances within the six-month timeframe.
You may also be interested in...
Singapore recalls trigger international reaction as metformin is added to growing list of chronic medications found to contain NDMA.
Regulators in North America and Europe are reacting to the discovery of the impurity NMDA in ranitidine, just over a year after similar impurities in sartan products led to a slew of recalls and withdrawals around the world.
In the months since US and EU authorities restricted Zhejiang Huahai’s market access over the discovery of nitrosamine impurities in its valsartan API, the broader regulatory consequences for drug manufacturers are coming into focus.